Cymabay Therapeutics, Inc.

CymaBay Therapeutics, Inc. (www.cymabay.com) is a clinical-stage biopharmaceutical company. The company is focused on developing and providing access to therapies for patients with liver and other chronic diseases. Its pipeline includes three clinical stage product candidates, such as seladelpar, MBX-2982 and CB-0406. It also has one preclinical stage product candidate, CB-001. The Company's lead product candidate, seladelpar, is a potent and selective agonist of peroxisome proliferator activated receptor delta (PPARd), a nuclear receptor that regulates genes directly or indirectly involved in the synthesis of bile acids/sterols, metabolism of lipids and glucose, inflammation and fibrosis. Its MBX-2982 targets G protein-coupled receptor 119 (GPR119), a receptor that interacts with bioactive lipids known to stimulate glucose-dependent insulin secretion. Its CB-001 targets G protein-coupled receptor 120 (GPR120), a receptor for omega-3 fatty acids, such as docosahexaenoic acid (DHA).

• Cymabay Therapeutics, Inc.